Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Joel Freiman, M.D., MPH
Lexicon Pharmaceuticals, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Lexicon Investigational Site
Morrow, Georgia, United States
- Lexicon Investigational Site
Memphis, Tennessee, United States
- Lexicon Investigational Site
Austin, Texas, United States
- Lexicon Investigational Site
Houston, Texas, United States
- Lexicon Investigational Site
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2012
- Primary completion
- 30 Jun 2012
- Completion
- 30 Jun 2012
- Last update posted
- 14 Sept 2015
- Registered enrollment
- 63
- Registry id
- NCT01528111
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.